HIND
- BusinessWire
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
Vyome Holdings, Inc. (NASDAQ:HIND, "Vyome")), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended ...
- BusinessWire
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing ...
- BusinessWire
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1 VT-1953 regulatory ...
- BusinessWire
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome has signed an agreement with Impetis, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market¹ These next-generation JAK inhibitors are ...
- BusinessWire
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% ...
- BusinessWire
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") ...
- BusinessWire
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of ...
- BusinessWire
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026 Livechain, Inc. ("Livechain") (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), announced today that it has ...
- BusinessWire
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate human clinical data using the India innovation corridor in a very ...
- BusinessWire
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M Independent third-party assessment estimates a current VT-1953 ...
- BusinessWire
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product Vyome Holdings, Inc. ("Vyome" or the "Company") (NASDAQ:HIND) announced it has ...
- BusinessWire
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching USD 600 million for VT-1953 Independent valuation analysis estimates ...
- BusinessWire
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Vyome Board completes review of strategic alternatives for LICH, executes critical first step in building a scalable, standalone business Vyome Holdings, Inc. ("Vyome') (NASDAQ:HIND) announced its subsidiary, ...
- BusinessWire
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002). Patient-reported impact of ...
- BusinessWire
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia ...
- BusinessWire
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
(Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant ...
- BusinessWire
Vyome Holdings Announces Results of Annual Shareholder Meeting
All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) announced it held its annual shareholder meeting on October 28, ...
- BusinessWire
Vyome Holdings Acquires MIT AI Spinout Oculo Health
Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets ...
- BusinessWire
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard ...
- BusinessWire
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
VT-1953 continues to significantly improve the primary endpoint Co-founder Dr. Shiladitya Sengupta to discuss over a live video conference VT-1953 treatment significantly reduced malignant fungating wound-associated ...
- BusinessWire
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
Vyome seeks to access multi-billion-dollar AI-enabled medical device market Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an ...
- BusinessWire
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
Vyome owns 70% of Livechain; Board focused on value creation Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced its Board of Directors has agreed to conduct a ...
- BusinessWire
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Celebrates Indian Independence Day by Honoring the US-India Innovation Partnership Vyome Holdings (NASDAQ:HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US ...